Nipent (Pentostatin)

Pentostatin, the active ingredient in Nipent, is a purine analog antimetabolite presented as a solution for injection for intravenous use. It is employed in the treatment of hairy cell leukemia and chronic lymphocytic leukemia in adult patients, targeting malignant lymphocytes to inhibit disease progression. The drug acts by inhibiting adenosine deaminase, leading to accumulation of toxic nucleotides within lymphocytes, which results in apoptosis of the malignant cells.

GNH USA supplies Nipent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pentostatin is used in the treatment of hematologic malignancies that involve B‑cell lymphocytes.

Hairy cell leukemia: induces remission by targeting malignant B‑cells and reducing disease burden. Chronic lymphocytic leukemia: decreases leukemic cell proliferation and prolongs patient survival. B‑cell non‑Hodgkin lymphoma (in combination regimens): contributes to disease control when other agents have failed.

Pentostatin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Fever and chills - Myelosuppression (low blood cell counts) - Infections (upper respiratory, urinary) - Anemia

Serious or Rare Side Effects: - Severe neutropenia leading to opportunistic infections - Hepatic toxicity (elevated transaminases, jaundice) - Renal impairment or failure - Severe allergic reactions (anaphylaxis) - Life‑threatening bleeding due to thrombocytopenia

When using Pentostatin, several precautions should be observed to minimize risks and ensure safe administration.

Monitor blood counts: perform regular complete blood count assessments to detect myelosuppression. Assess renal function: evaluate creatinine clearance before each dose and adjust as needed. Evaluate hepatic function: check liver enzymes periodically. Avoid use in active infection: postpone treatment if patient has uncontrolled infection. Use contraception: both male and female patients should use effective contraception during therapy and for a defined period after. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pentostatin can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Concomitant use with other myelosuppressive agents (e.g., chemotherapy, azathioprine) may exacerbate bone‑marrow suppression. - Live vaccines: increased risk of infection; should be avoided during therapy. - Allopurinol: may increase pentostatin toxicity and require dose adjustment.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole) may alter drug metabolism; monitor blood counts. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) can increase renal toxicity risk. - Anticoagulants: enhanced bleeding risk due to thrombocytopenia; monitor coagulation parameters.